- Previous Close
26.22 - Open
26.22 - Bid 33.84 x --
- Ask 34.32 x --
- Day's Range
26.22 - 26.22 - 52 Week Range
26.22 - 32.19 - Volume
354 - Avg. Volume
0 - Market Cap (intraday)
1.728B - Beta (5Y Monthly) 0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-0.92 - Earnings Date Feb 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
www.glpg.comRecent News: GLPGA.XC
View MorePerformance Overview: GLPGA.XC
Trailing total returns as of 12/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLPGA.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLPGA.XC
View MoreValuation Measures
Market Cap
1.69B
Enterprise Value
-1.64B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.63
Price/Book (mrq)
0.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
79.33%
Return on Assets (ttm)
-2.38%
Return on Equity (ttm)
-2.21%
Revenue (ttm)
260.09M
Net Income Avi to Common (ttm)
-60.61M
Diluted EPS (ttm)
-0.92
Balance Sheet and Cash Flow
Total Cash (mrq)
3.34B
Total Debt/Equity (mrq)
0.40%
Levered Free Cash Flow (ttm)
-283.03M